Brought to you by:
Downstream Column | Cell Culture Dish | Agilitech
Bridging the Gap Between Promise and Practicality
Gene Therapy Advancements, Challenges, and the Path to Commercial Success
Explore the Dynamic Landscape of Cell and Gene Therapy
The newly released white paper examines the dynamic landscape in cell and gene therapy, including therapeutic targets, manufacturing, and regulatory frameworks. Cell Culture Dish, alongside a panel of industry experts, including Dennis Hodgson from Agilitech, provides an updated look at the current state of the industry. They share insights on the industry’s current status and the upcoming challenges on the path to achieving widespread clinical success.
While the field is still evolving and there are challenges, this White Paper looks to the future, exploring the obstacles that remain on the path toward commercial success and highlighting the key opportunities for future advancement and sustainability.
White Paper Highlights:
State of the Current Cell and Gene Therapy Industry: The paper examines what’s currently working and what needs improvement.
Challenges Facing the Industry: It addresses potential issues due to the growing number of cell and gene therapies in clinical trials and outlines obstacles in viral vector manufacturing.
Lowering the Cost and Risk of Manufacturing: Potential solutions to mitigate manufacturing costs and risks are discussed.
What’s on the Horizon: Insights are provided on how automation will be incorporated into cell and gene therapy manufacturing and the feasibility of a platformable manufacturing solution.
This white paper is brought to you by:
About The Publisher
BRANDY SARGENT
Editor-in-chief
Cell Culture Dish & Downstream Column
Brandy Sargent is the Editor in-chief and frequent author of The Cell Culture Dish and The Downstream Column. She has worked in the biotechnology industry for over twenty years, first in corporate communications and public relations, then in technical sales and marketing, and most recently as a writer and publisher. She strives to introduce topics that are interesting, thought provoking, and possible starting points for discussion by the biomanufacturing community. She has been fascinated by the different applications of biotechnology since she first started working in the industry and continues to be fascinated as the industry evolves.
